AbbVie

Court Rules Against Whistleblower in AbbVie Case: Regulatory Concerns Fall Short of False Claims Act Protection

by

SOUTH BEND, Ind. — The 7th Circuit Court of Appeals recently upheld a lower court’s dismissal of a lawsuit filed by Jeffrey Lewis against AbbVie Inc., previously known as Allergan. The court found that Lewis’s claims did not meet the necessary criteria under the False Claims Act, which addresses fraud against government programs. The case, officially designated as 24-3121, was initiated by Lewis in response to concerns he raised internally regarding AbbVie’s regulatory practices. However, the appeals court determined that these communications did not demonstrate any allegations of fraud, which is a key component for … Read more

AbbVie Secures $56M in Royalty Victory Over Revance in Botox Patent Dispute

by

CHICAGO – AbbVie has secured a significant legal victory in its ongoing battle over Botox-related patents. A jury has awarded the pharmaceutical company $56 million in royalties from Revance Therapeutics, affirming AbbVie’s claims of patent infringement. The case revolved around a contested patent for the use of a specific botulinum toxin formulation, which AbbVie argued Revance had violated with its own injectable therapy. This ruling underscores AbbVie’s commitment to protecting its intellectual property, particularly given the competitive landscape in the cosmetic and therapeutic market for neuromodulators. AbbVie has been a dominant player in the botulinum … Read more